In a patient with an ejection fraction of 40% and an estimated creatinine clearance of 35 mL/min, what guideline‑directed heart‑failure medications should be started?

Initiate Quadruple Therapy Immediately with Dose Adjustments for Renal Function

In a patient with EF 40% and eCrCl 35 mL/min, you should start all four foundational GDMT classes now: an ACE inhibitor (or ARNI if tolerated), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor, with careful monitoring and dose modifications based on renal function. 1, 2

The Four Pillars of GDMT for HFrEF

The 2022 AHA/ACC/HFSA guidelines establish four medication classes as foundational therapy 1, 2:

1. Renin-angiotensin system inhibition (ACE inhibitor, ARB, or ARNI)
2. Evidence-based beta-blockers (carvedilol, metoprolol succinate, or bisoprolol)
3. Mineralocorticoid receptor antagonists (spironolactone or eplerenone)
4. SGLT2 inhibitors (dapagliflozin or empagliflozin)

All four classes carry Class I recommendations for reducing mortality and heart failure hospitalization 1, 3.

Specific Recommendations for eCrCl 35 mL/min

1. ACE Inhibitor or ARNI

• Start with an ACE inhibitor at low dose (e.g., enalapril 2.5 mg twice daily or lisinopril 2.5 mg daily) 4, 5
• ACE inhibitors should be started in all patients with LVEF <40% unless contraindicated 4, 5
• Monitor: Expect up to 30% increase in creatinine—this is acceptable and does not require stopping the drug 6
• ARNI consideration: Sacubitril/valsartan is NOT recommended with eGFR <30 mL/min/1.73m² 7, so with eCrCl 35, you're borderline—start with ACE inhibitor first, then consider switching to ARNI once renal function stabilizes

2. Beta-Blocker

• Start immediately with carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily 1, 8, 3
• Of these three, only bisoprolol may accumulate with renal impairment, but still titrate to target dose based on clinical response 7
• Beta-blockers are Class I, Level A evidence for mortality reduction 5, 3
• Titrate slowly: Double the dose every 2-4 weeks to target doses 6, 8

3. Mineralocorticoid Receptor Antagonist

• Start spironolactone at LOW dose: 12.5 mg daily or even 12.5 mg every other day given the renal impairment 7, 9
• MRAs are recommended with eGFR ≥30 mL/min/1.73m² 7
• Critical monitoring: Check potassium and creatinine within 3-7 days, then weekly for first month 6
• Hold if potassium >5.0-5.2 mmol/L or creatinine rises significantly 6
• This is Class I, Level A evidence for patients with LVEF <40% 4, 5, 3

4. SGLT2 Inhibitor

• Start dapagliflozin 10 mg daily (approved for eGFR ≥25 mL/min/1.73m²) or empagliflozin 10 mg daily (approved for eGFR ≥20 mL/min/1.73m²) 7
• With eCrCl 35, both are safe to initiate 7
• Benefits emerge within weeks of starting 10
• Monitor: Watch for volume depletion due to osmotic diuretic effect 7
• This is now Class I recommendation in the 2022 guidelines 1, 2

Practical Implementation Strategy

"Four drugs in 4 weeks" approach 10:

• Week 1: Start beta-blocker + SGLT2 inhibitor (safest, fewest interactions)
• Week 2: Add ACE inhibitor at low dose, check labs in 3-7 days
• Week 3-4: Add MRA at very low dose (12.5 mg daily or every other day), check potassium and creatinine in 3-7 days

Critical Monitoring Parameters

• Baseline labs: Creatinine, potassium, BUN
• After starting ACE inhibitor: Recheck in 1-2 weeks—accept up to 30% creatinine increase if stable 6
• After starting MRA: Recheck potassium and creatinine in 3-7 days, then weekly for first month 6, 9
• Blood pressure: Check supine and standing to detect symptomatic hypotension 6

Common Pitfalls to Avoid

1. Don't withhold therapy due to "borderline" renal function—the evidence shows GDMT is safe and beneficial even with CKD stage 3b 7, 11
2. Don't use therapeutic inertia as an excuse—renal impairment was the major factor for GDMT underprescription, but studies show no increased risk of adverse renal outcomes 11
3. Don't combine ACE inhibitor + ARB + MRA—this triple combination increases hyperkalemia risk 6, 3
4. Don't stop drugs for asymptomatic lab changes—only adjust for symptomatic hypotension or persistent hyperkalemia >5.5 mmol/L 6

Uptitration Strategy

After initiating all four classes, titrate to target doses over 6-12 weeks 12:

• Carvedilol: Target 25 mg twice daily
• Metoprolol succinate: Target 200 mg daily
• Bisoprolol: Target 10 mg daily
• ACE inhibitor: Target dose (e.g., enalapril 10 mg twice daily, lisinopril 20-40 mg daily)
• Spironolactone: Target 25-50 mg daily (if tolerated)
• SGLT2 inhibitor: Already at target dose (10 mg daily)

Evidence Supporting Early Initiation

Starting ≥3 pillars of GDMT at hospital discharge reduces all-cause mortality (HR 0.22), CV death (HR 0.21), and HF hospitalization (HR 0.28) compared to <3 pillars 11. The cumulative 1-year incidence of death or HF hospitalization was 56.3% with 0 GDMT classes vs. 25.1% with 3 classes 13. Each additional GDMT class provides incremental benefit 14, 13.

The presence of CKD should not preclude GDMT initiation—studies demonstrate tolerability and safety even in patients with advanced age or renal dysfunction 9, 15.